Compare Sea Limited (SE) vs Summit Therapeutics Inc (SMMT) Price & Performance

Sea Limited (SE) trades at $95.25, down 0.62% with a bearish technical signal. The company shows strong fundamental improvement with revenue growing from $12.4B in 2022 to $22.9B in 2025, achieving profitability with net income of $1.58B. Analyst consensus remains strongly bullish with 70% buy ratings and a $153.67 price target, though recent insider selling and technical weakness create near-term headwinds. Operating cash flow has turned positive at $5.02B, supporting the company's growth trajectory.

Sea Limited presents a compelling growth story with improving profitability and strong analyst support, though technical weakness and insider selling warrant caution. The stock trades at a discount to analyst targets with solid fundamentals, but investors should monitor execution risks in competitive e-commerce and digital entertainment markets. The current price level near support at $91-92 offers potential entry for long-term investors.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.